Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05476783 · ClinicalTrials.gov registry record · Phase 2
A Long Term Extension Study to Assess the Safety of TB006 in Participants With Alzheimer's Disease
A Phase 2 study, sponsored by TrueBinding.
- Terminated
- Registry status
- Phase 2
- Development phase
- 119
- Enrollment target
NCT05476783 is a Phase 2 study that was terminated before completion, run by TrueBinding. The registered enrollment target is 119 participants.
The verdict
NCT05476783, a Phase 2 study, was terminated before completion, sponsored by TrueBinding.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 119 participants
- Enrollment target
Study Summary
This is an open-label long term extension study for participants with Alzheimer's disease (AD) who have completed Protocol TB006AD2102 (lead-in study) or participants who would have been eligible for the lead-in study but were not enrolled (de novo). The study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TB006. The total study duration for each participant will be up to 113 weeks.
Interventions
- DRUG TB006
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2022-09-15 |
| Est. Completion | 2023-11-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05476783
The ClinicalTrials.gov registry entry for NCT05476783 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TrueBinding, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TB006 is the first listed.
NCT05476783 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05476783 about?
NCT05476783 is a clinical study titled "A Long Term Extension Study to Assess the Safety of TB006 in Participants With Alzheimer's Disease". This is an open-label long term extension study for participants with Alzheimer's disease (AD) who have completed Protocol TB006AD2102 (lead-in study) or participants who would have been eligible for the lead-in study but were not enrolled (de novo). The study is designed to evaluate the safety, tol...
What is the current status of trial NCT05476783?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 119 participants. The study started on 2022-09-15. Estimated completion is 2023-11-17.
What interventions are being tested in trial NCT05476783?
The interventions under investigation include: TB006 (DRUG).
Who is sponsoring clinical trial NCT05476783?
This trial is sponsored by TrueBinding, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.